Literature DB >> 11482984

Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers.

R I Mahato1, M Lee, S Han , A Maheshwari, S W Kim.   

Abstract

Our objective was to design a water-soluble lipopolymer (WSLP) and an interleukin-12 (IL-12) expression plasmid for enhanced delivery of the IL-12 gene. We synthesized WSLP using branched polyethylenimine (PEI) of 1800 Da and cholesteryl chloroformate, and constructed p2CMVmIL-12, encoding the IL-12 subunits p35 and p40, each under the transcriptional control of a separate cytomegalovirus (CMV) promoter. The percentage of cholesterol conjugated to PEI was about 47% and the average molecular weight of WSLP was approximately 2000 Da. The mean particle size of WSLP/p2CMVmIL-12 complexes formulated in 5% glucose was 26 to 62 nm and xi potential was 8 to 60 mV. The WSLP/p2CMVmIL-12 complexes were nontoxic to CT-26 colon carcinoma cells at the N/P ratio (nitrogen atoms of WSLP/phosphate of plasmid DNA) of 20 and below; PEI25000/pDNA complexes were highly toxic. WSLP/p2CMVmIL-12 complexes demonstrated higher transfection in CT-26 cells compared with the DNA formulations prepared using PEI of molecular weights 1800, 10,000 and 25,000 Da. Transfection efficiency increased with an increase in N/P ratios from 5 to 15, then there was no significant increase in transfection up to the N/P ratio of 30/1. There was an increase in the level of IL-12 when free or complexed p2CMVmIL-12 was compared with free or complexed pIRESmIL-12 in which the p35 and p40 subunits were linked to the internal ribosome entry sites (IRES). At 48 hours post-injection of WSLP/p2CMVmIL-12 complexes into BALB/c mice bearing CT-26 subcutaneous tumors, the levels of IL-12, IFN-gamma, and nitric oxide (NO) in the supernatant of the cultured tumors were higher for the WSLP/p2CMVmIL-12 complexes than for the naked p2CMVmIL-12, WSLP, and 5% glucose injected groups. There was a significant improvement in the survival rate and the inhibition of tumor growth after a single injection of WSLP/p2CMVmIL-12 complexes. We have designed an effective, nontoxic WSLP and an IL-12 expression plasmid with two CMV promoters.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11482984     DOI: 10.1006/mthe.2001.0425

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  14 in total

Review 1.  Lipid-based nanoparticles for nucleic acid delivery.

Authors:  Weijun Li; Francis C Szoka
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

2.  Paclitaxel-conjugated PEG and arginine-grafted bioreducible poly (disulfide amine) micelles for co-delivery of drug and gene.

Authors:  Kihoon Nam; Hye Yeong Nam; Pyung-Hwan Kim; Sung Wan Kim
Journal:  Biomaterials       Date:  2012-08-04       Impact factor: 12.479

3.  Novel water insoluble lipoparticulates for gene delivery.

Authors:  Darin Y Furgeson; Richard N Cohen; Ram I Mahato; Sung Wan Kim
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

4.  Biomaterials to gene delivery.

Authors:  Sung Wan Kim
Journal:  J Control Release       Date:  2011-03-30       Impact factor: 9.776

Review 5.  Gene therapy: implications for craniofacial regeneration.

Authors:  Erica L Scheller; Luis G Villa-Diaz; Paul H Krebsbach
Journal:  J Craniofac Surg       Date:  2012-01       Impact factor: 1.046

Review 6.  Women and heart disease--physiologic regulation of gene delivery and expression: bioreducible polymers and ischemia-inducible gene therapies for the treatment of ischemic heart disease.

Authors:  James W Yockman; Sung Wan Kim; David A Bull
Journal:  Adv Drug Deliv Rev       Date:  2009-05-05       Impact factor: 15.470

Review 7.  Gene therapy: design and prospects for craniofacial regeneration.

Authors:  E L Scheller; P H Krebsbach
Journal:  J Dent Res       Date:  2009-07       Impact factor: 6.116

Review 8.  Localized Interleukin-12 for Cancer Immunotherapy.

Authors:  Khue G Nguyen; Maura R Vrabel; Siena M Mantooth; Jared J Hopkins; Ethan S Wagner; Taylor A Gabaldon; David A Zaharoff
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

9.  Bipartite vector encoding hVEGF and hIL-1Ra for ex vivo transduction into human islets.

Authors:  Ravikiran Panakanti; Ram I Mahato
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

10.  Bipartite vectors for co-expression of a growth factor cDNA and short hairpin RNA against an apoptotic gene.

Authors:  Feng Li; Ram I Mahato
Journal:  J Gene Med       Date:  2009-09       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.